Zenidatamab regimens show survival benefit in HER2-positive gastric cancer, but PD-L1 test variability raises treatment questions

The HERIZON‑GEA‑01 study reports that zenidatamab‑based treatment schedules lead to a notable improvement in overall survival for patients with HER2‑positive gastric cancer.

These efficacy findings suggest the regimen could become an important option for this disease subgroup, offering a potential advance over existing therapies.

However, the report also highlights that differences in PD‑L1 testing methods create uncertainty about how best to select patients for the therapy, indicating a need for clearer diagnostic guidance.